Optimum Perspectives

Hosted on Acast. See acast.com/privacy for more information.

There is a lack of effective treatments for Cutaneous T-Cell Lymphoma (CTCL) – in this podcast episode Jason Loveridge, CEO of 4SC, talked to Optimum Strategic Communications’ Eva Haas about the Company’s potential new maintenance therapy Kinselby (resminostat).

4SC is a late-stage biotech improving lives for patients suffering with advanced-stage Cutaneous T Cell Lymphoma (CTCL).

It has developed Kinselby (resminostat), a novel, oral, maintenance treatment targeting advanced-CTCL, a rare type of non-Hodgkin lymphoma that affects the skin. There are no drugs in development or on the market as maintenance therapy for CTCL.

Kinselby (resminostat) is an orally administered histone deacetylase (HDAC) inhibitor that has produced supportive results in the pivotal RESMAIN trial, where it postponed disease progression in patients – a new treatment paradigm in CTCL.

Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.

Alchemab aims to revolutionise drug discovery with a novel alternative to the classic “choose a target” approach. 

Alchemab specifically looks to identify shared antibodies from people who have shown resilience to disease – the unexpectedly well. The company then uses its proprietary technology to identify which targets these antibodies are binding to, and what diseases these targets are associated with.  

Optimum Strategic Communications’ Richard Staines caught up with Alchemab’s CEO, Young Kwon, to find out more. 

Hosted on Acast. See acast.com/privacy for more information.

No-one is likely to forget the tragic events of 2020 and one company leading efforts to prepare for the next pandemic is Poolbeg Pharma.

Optimum Strategic Communications’ Richard Staines interviewed CEO Jeremy Skillington to find out how Poolbeg is using AI to expedite discovery of new flu drugs.

Poolbeg is working on a drug that aims to block some of the worst effects of influenza, neutralising the over-reaction from the body’s immune system known as a “cytokine storm” that produces many of the ill effects following a flu infection. 

Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.

Today’s funding environment for small biotechs is tough. Valuations are down and money is tighter than it used to be – both for publicly listed and privately held firms.  

In these circumstances, obtaining the right backing – both in terms of finance and managerial advice – is more important than ever. 

In the fifth Optimum Perspectives podcast experienced investor Søren Møller talks to Optimum’s Stephen Adams about Novo Holdings Seed Investments’ approach to working with biotechs and what early-stage companies should look for in a financing partner. 

Hosted on Acast. See acast.com/privacy for more information.

How do you take a tiny private Swedish biotech and turn it into a successful, publicly-listed company operating on both sides of the Atlantic, in just six years?

Listen to Renée Aguiar-Lucander, CEO of Calliditas Therapeutics, tell Optimum’s Richard Staines how they brought TARPEYO, the first FDA-approved drug for the rare kidney disease primary IgA nephropathy, to market.

She describes her ‘incredible journey’ growing the firm from less than 10 staff to more than 200, taking it public in Europe and the US, running a global Phase III trial, and how Tarpeyo can help people with IgA nephropathy live more normal lives.

https://www.optimumcomms.com/podcast

Follow us and subscribe for new episodes highlighting the latest innovation and developments in life sciences, with industry leaders of the healthcare sector.

Available on all major platforms: Apple, Spotify, Google, Amazon Music, Tune In, Castbox, Deezer and more! 

Follow and Subscribe today. #optimumperspectivespodcast

Hosted on Acast. See acast.com/privacy for more information.

In this episode, our in-house IR expert, and ex-Fund Manager Eva Haas interviewed Dan Mahony, Chairman of the BioIndustry Association (BIA), following his appointment as UK Life Sciences Investment Envoy to hear his plans for championing the UK’s Life Sciences industry. Read the insight piece here: An interview with Dan Mahony, UK Government Life Sciences Envoy by Optimum’s Eva Haas

https://www.optimumcomms.com/podcast

Follow us and subscribe for new episodes highlighting the latest innovation and developments in life sciences, with industry leaders of the healthcare sector.

Available on all major platforms: Apple, Spotify, Google, Amazon Music, Tune In, Castbox, Deezer and more! 

Follow and Subscribe today. #optimumperspectivespodcast

Hosted on Acast. See acast.com/privacy for more information.